What are “human challenge” trials, and how might they help in efforts to develop a vaccine against COVID-19? Neil McNeil talks to Kate Bingham, chair of the UK Vaccine Task Force; Peter Openshaw, Professor of Experimental Medicine at Imperial College London, Dr. Andrew Catchpole, Chief Scientific Officer at hVIVO, and Sean Cousins, a volunteer participant in several human challenge trials.

Efforts to develop a vaccine have been underway for months.  For the latest news on when it might arrive – and whether we’ll need more than one - Neil McNeil speaks to Kate Bingham, Chair of the UK Vaccine Task Force; Dr. Helen Horton, Chief Research Officer at Touchlight Genetics Ltd and scientific advisor to the vaccine task force;  Saul Faust, Professor of Paediatric Immunology and Infectious Diseases at the University of Southampton, and Dr. Clive Dix, Vice-Chair of the UK Vaccine Task Force.

Developing a vaccine is one thing, but manufacturing it in very large amounts is a significant challenge in itself.  In this episode, Neil McNeil is joined by Kate Bingham, chair of the UK Vaccine Task Force, Netty England, member of the BIA Manufacturing Advisory Committee, Andy Jones, Industrial Strategy Challenge Fund Medicines Manufacturing Director, and Ian McCubbin, Vaccine Task Force Manufacturing Lead, to find out what’s involved and what’s being done to get ready for large-scale manufacture.